Identification of an m6A RNA Methylation Regulator Risk Score Model for Prediction of Clinical Prognosis in Astrocytoma.

Fangzhou Guo,Hainan Chen,Ligen Mo,Guoyuan Ling,Junbo Mu,Liu Shi,Jun Yan,Teng Deng,Pinghua Wu,Qianrong Huang,Osamah Ibrahim Khalaf

doi:10.1155/2022/7168929

Abstract

Astrocytoma (AS) is the most ubiquitous primary malignancy of the central nervous system (CNS). The vital involvement of the N6-methyladenosine (m6A) RNA modification in the growth of multiple human tumors is known. This study entailed probing m6A regulators with AS prognosis to construct a risk prediction model (RS) for potential clinical use. A total of 579 AS patients' (of the Chinese Glioma Genome Atlas,CGGA) data and the expression of 12 published m6A-related genes were included in this study. Cox and selection operator (LASSO) regression analyses for independent prognostic factors and multifactor Cox analysis established an R.S. model to predict the AS patient prognosis. This was subject to verification employing 331 samples from the TCGA data set followed by gene ontology and pathway enrichment study with gene set enrichment analysis (GSEA). The R.S. constructed with three m6A genes inclusive of WTAP, RBM15, and YTHDF2 emerged as independent prognostic factors in AS patients with vital involvement in the advancement and development of the malignancy. In a nutshell, this work reported an m6A-related gene risk model to predict the prognosis of AS patients to pave the way for discerning diagnostic and prognostic biomarkers. Further corroboration employing relevant wet-lab assays of this model is warranted.

Highlights

Astrocytoma (AS) is the most ubiquitous intracranial malignancy, accounting for 40-50% of primary central nervous system (CNS) tumors
The m6A regulatory variables are being investigated in silico to determine their expression status, prognostic significance, and biological roles
A risk model comprising three m6A regulatory genes is being developed as part of this research

Summary

Introduction

Astrocytoma (AS) is the most ubiquitous intracranial malignancy, accounting for 40-50% of primary CNS tumors. Most tumors document a higher recurrence rate post-esection with the occurrence of a higher grade and more aggressive tumor type in the event of relapse. Notwithstanding the extensive use of comprehensive treatment approaches inclusive of surgical resection, radiotherapy, and chemotherapy, the 5-year survival rate of highly aggressive AS is still less than 20%. Another roadblock is the high disability rate after surgery that seriously impacts the patients’ quality of life [3]. Prognosis prediction and treatment guidance employ traditional clinical risk factors, including tumor grade, preoperative imaging, and IDH gene silencing status. Useful molecular indicators as possible treatment targets have yet to be discovered [4, 5]

Methods

Results

Discussion

Conclusion